Bioversys AG (BIOV.SW) stock: key figures, P/E, revenue and dividend
Health Care · Switzerland · ISIN CH0210362643
Bioversys AG financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 CHF | 800,000.00 CHF |
| Gross profit | -3.95 m CHF | -3.09 m CHF |
| Operating income | -18.72 m CHF | -19.96 m CHF |
| EBIT | -17.68 m CHF | -20.74 m CHF |
| Net income | -18.72 m CHF | -21.83 m CHF |
| Diluted EPS – continuing operations | -3.16 CHF | -3.73 CHF |
Full history since 2024, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Bioversys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
More stocks
- Petronor E&P Ltd (PNOR.OL)
- Capitan Silver Corp. (CAPT.V)
- BaaS Innovation Co., Ltd. (3555.TWO)
- Golden Ventures Leasehold Real Estate Investment Trust (GVREIT.BK)
- Advance Materials Corporation (3585.TWO)
- Mosel Vitelic Inc (2342.TW)
- Miwon Chemical (134380.KS)
- CuriosityStream Inc. (CURI)
- Super Turtle PCL (TURTLE.BK)
- Deezer S.A. (DEEZR.PA)
- AirJoule Technologies Corp. (AIRJ)
- Fiera Capital Corporation (FSZ.TO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.